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TRIM5α and TRIMCyp are retroviral restriction factors that, like other members of the tripartite motif (TRIM) family, contain RING, B-box 2
and coiled-coil domains. We found that both proteins are rapidly turned over, with half-lives of 50–60 min. Polyubiquitylation and rapid
degradation of TRIM5α depended upon intact RING and B-box 2 domains. A chimera consisting of monkey TRIM5α with a RING domain of
human TRIM21 exhibited a half-life of 210 min, yet potently restricted human immunodeficiency virus; therefore, rapid turnover of TRIM5α is
not required for its antiretroviral activity. TRIM5α forms cytoplasmic bodies that contain other polyubiquitylated proteins, heat shock proteins and
dynein, and thus resemble aggresome precursors. Consistent with this interpretation, proteasomal inhibitors triggered the formation of TRIM5αrh-
containing aggresomes in a microtubule-dependent manner. Thus, TRIM5α levels in the cell are maintained by continuous synthesis and rapid
proteasome-mediated degradation, imbalances in which result in the formation of pre-aggresomal cytoplasmic bodies.
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Proteins of the tripartite motif (TRIM) family contain RING,
B-box and coiled-coil domains and thus have also been referred
to as RBCC proteins. TRIM proteins often self-associate and
form nuclear or cytoplasmic bodies (Reymond et al., 2001). The
number of TRIM genes has greatly increased during vertebrate
evolution, although the natural function of most TRIM proteins
is unknown.
TRIM5α is a cytoplasmic protein that is capable of restricting
retrovirus infection in a species-dependent manner (Stremlau
et al., 2004). Variation among TRIM5α proteins in different
primates accounts for the early, post-entry blocks to infection by
particular retroviruses (Hatziioannou et al., 2004; Keckesova et⁎ Corresponding author. Department of Cancer Immunology and AIDS, Dana-
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2004; Yap et al., 2004). For example, TRIM5α proteins of Old
World monkeys block human immunodeficiency virus (HIV-1)
infection (Hatziioannou et al., 2004; Keckesova et al., 2004;
Stremlau et al., 2004; Yap et al., 2004), whereas TRIM5α
proteins of New World monkeys block infection by simian
immunodeficiency virus (SIVmac) (Song et al., 2005a). TRIM5α
from humans (TRIM5αhu) is not as potent in restricting HIV-1
infection as Old World monkey TRIM5α, but TRIM5αhu
potently restricts other retroviruses, e.g., N-tropic murine leuke-
mia virus (N-MLV) and equine infectious anemia virus (EIAV)
(Hatziioannou et al., 2004; Perron et al., 2004; Song et al.,
2005a; Stremlau et al., 2004; Yap et al., 2004). Owl monkeys are
unusual in not expressing a TRIM5α protein, but instead express
TRIMCyp, in which the RBCC domains of TRIM5 are fused to
a cyclophilin A moiety (Nisole et al., 2004; Sayah et al., 2004).
Variation in splicing of the TRIM5 primary transcript leads to
the expression of TRIM5 isoforms, designated α, γ and δ
(Reymond et al., 2001). The TRIM5α isoform contains, in
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carboxy-terminal B30.2(SPRY) domain. The B30.2(SPRY)
domain is essential for the antiretroviral activity of TRIM5α
(Stremlau et al., 2004). In some cases, the differences in the
ability of TRIM5α proteins from various primate species to
restrict particular retroviruses are determined by sequences in
the B30.2(SPRY) domain (Stremlau et al., 2005; Nakayama et
al., 2005; Yap et al., 2005; Sawyer et al., 2005; Perez-Caballero
et al., 2005). Disruption of the B-box 2 domain of rhesus
monkey TRIM5α (TRIM5αrh) also eliminates the ability of the
protein to restrict HIV-1 infection (Javanbakht et al., 2005;
Perez-Caballero et al., 2005). Deletion of the RING domain
decreases, but does not eliminate, TRIM5αrh-mediated restric-
tion of HIV-1 infection (Javanbakht et al., 2005; Perez-
Caballero et al., 2005).
TRIM5, like other TRIM proteins, self-associates to form
cytoplasmic bodies when overexpressed in cells (Reymond et
al., 2001; Xu et al., 2003; Song et al., 2005b). The nature and
function of cytoplasmic bodies are unknown, but they are not
required for the antiretroviral activity of rhesus monkey
TRIM5α (Song et al., 2005b; Perez-Caballero et al., 2005).
Here, we study the intracellular location, synthesis and
turnover of wild-type TRIM5αrh and TRIMCyp and variants
of these proteins with deletion or disruption of particular
TRIM5 domains. We document several unusual features of
TRIM5α and TRIMCyp, i.e., their rapid turnover, polyubi-
quitylation and association with pre-aggresomal structures in
the cell. We show the importance of RING and B-box 2
domains to the polyubiquitylation and degradation of these
proteins by the proteasome. Finally, we investigate the
contribution of rapid turnover to the antiviral activity of
TRIM5α.
Results
TRIM5αrh and TRIM5αhu are short-lived proteins
The rhesus monkey and human TRIM5 variants studied
herein are depicted in Fig. 1A. In addition to TRIM5 mutants
with domain deletions, the C15A/C18A and C97A/H100A
mutants, in which the TRIM5αrh RING and B-box 2 domains,
respectively, are disrupted (Stremlau et al., 2004; Javanbakht et
al., 2005), were studied. These proteins were stably expressed
in HeLa cells. The steady-state levels of these proteins were
analyzed by Western blotting cell lysates with an antibody
directed against the carboxy-terminal HA epitope tag (Fig.
1B). Compared with the expression of the wild-type TRIM5αrh
protein, the levels of the Δ93, C15A, C15A/C18A and C97A/
H100A mutants were slightly higher. The Δ132 mutant was
expressed at significantly higher levels than the wild-type
TRIM5αrh protein. To investigate these differences, we
determined the turnover rates of the TRIM5 variants by
treating the HeLa cells with cycloheximide for a period of 12
h and assessing the level of TRIM5 protein expression at
different time points after the initiation of cycloheximide
treatment (Fig. 2A). Remarkably, after only 3 h of treatment
with the drug, TRIM5αrh and TRIM5αhu levels were almostundetectable. Interestingly, TRIM5γrh, a TRIM5 isoform that
does not contain the B30.2(SPRY) domain (Fig. 1A), exhibited
a similar rate of degradation (Fig. 2A). The approximate half-
lives of TRIM5αrh, TRIM5αhu and TRIM5γrh were 52, 57 and
64 min, respectively. TRIM5αrh exhibited a similar rate of
degradation in Cf2Th cells canine thymocytes (data not
shown). We conclude that wild-type human and monkey
TRIM5α proteins are turned over very rapidly in these
transduced cells. The rapid degradation of the TRIM5γrh
protein further suggests that the B30.2(SPRY) domain is not
needed for this fast turnover.
The TRIM5αrh RING and B-box 2 domains are important for
rapid degradation
To address the possible role of the RING and B-box 2
domains in the rapid degradation of TRIM5αrh, we measured
the half-lives of TRIM5αrh proteins containing deletions and
single amino acid changes affecting the RING and B-box 2
domains (Fig. 1A). Interestingly, we observed two different
rates of degradation for these mutants. Mutants containing
single amino acid changes designed to disrupt zinc binding of
the RING and B-box 2 domains (C15A/C18A and C97A/
H100, respectively) were degraded at a slower rate (half-lives
of 124 and 148 min, respectively) than the wild-type protein
(Figs. 2A and B). The TRIM5αrhΔ93 mutant, which lacks the
RING domain, also exhibited a half-life of 124 min. A much
slower rate of turnover (half-life of 764 min) was observed for
the mutant (TRIM5αrhΔ132) with a deletion encompassing
both the RING and B-box 2 domains (Figs. 2A and B). This
half-life approached that seen for β-actin (Figs. 2A and B).
These results suggest that the presence of an intact RING and
B-box 2 domain contributes to the rapid degradation of
TRIM5αrh.
TRIMCyp is a protein from owl monkeys that can restrict
HIV-1 infection (Nisole et al., 2004; Sayah et al., 2004).
TRIMCyp consists of the RING, B-box 2 and coiled coil
domains of TRIM5 fused with cyclophilin A. TRIMCyp
exhibited a decay rate similar to that of TRIM5αrh (Fig. 2C).
TRIMCypΔ93, which lacks the RING domain, exhibited a
steady-state level higher than that of TRIMCyp (Fig. 2C).
The turnover rate of the TRIMCypΔ93 protein was very
slow, consistent with a role for the RING domain in the
degradation of TRIMCyp. The decay rate of the TRIM-
CypΔ130 protein, which lacks RING and B-box 2 domains,
was only slightly slower than that of wild-type TRIMCyp
(Fig. 2C). Thus, deletion of the RING and B-box 2 domains
results in different effects on the turnover of TRIM5αrh and
TRIMCyp proteins.
Proteasomal inhibitors decrease the degradation of TRIM5α
and TRIMCyp
To evaluate the role of the proteasome in the rapid turnover
of TRIM5αrh and TRIM5αhu, TRIM5α levels were measured in
the presence and absence of the proteasomal inhibitors, MG115
and lactacystin. The effects of proteasomal inhibitors were also
Fig. 1. Wild-type and mutant TRIM5αrh proteins. (A) The wild-type TRIM5αrh protein is depicted in the top figure. The numbers of the amino acid residues at the
boundaries of the TRIM5αrh domains are shown. The carboxyl-terminus of the protein contains a hemagglutinin (HA) epitope tag. The mutant TRIM5αrh proteins are
shown, with the absence of boxes indicating deleted sequences. The positions of individual amino acid changes are indicated. (B) HeLa cells were transduced with
pLPCX vectors expressing the indicated TRIM5 variants or with the control empty pLPCX vector. Cell lysates were Western blotted and probed with antibodies
directed against either the HA epitope tag (top panel) or β-actin (bottom panel).
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control cells treated with the DMSO solvent only, cells treated
with the proteasomal inhibitors MG115 or lactacystin exhibited
slight increases in TRIM5α levels over time (Figs. 3A and B
and data not shown). Compared with the initial levels of protein,
this increase was 1.5- and 4-fold for TRIM5αrh and TRIM5αhu,
respectively. We also measured the effect of MG115 on the rate
of TRIM5α degradation in the presence of cycloheximide.
MG115 decreased the turnover of TRIM5αrh and TRIM5αhu in
this context as well (Figs. 3A and B). These results indicated
that the proteasome contributes to the degradation of TRIM5αrh
and TRIM5αhu. Similarly, treatment of cells synthesizing
TRIMCyp with the proteasomal inhibitor MG115 resulted in
an increase in the steady-state levels of TRIMCyp expression
(Fig. 3C).Most cytoplasmic proteins are degraded in the proteasome;
another protein degradation pathway, most often used for
transmembrane proteins, occurs in the lysosome (Cuervo and
Dice, 1998). To test if degradation of TRIM5αrh involves the
lysosomal pathway, we measured the half-life of this protein in
the presence of ammonium chloride (Fig. 3D). This lysosomo-
tropic agent did not change the half-life of TRIM5αrh,
suggesting that the lysosome contributes minimally to the
degradation of TRIM5αrh. Together, these results suggest that
TRIM5α is mainly degraded in the proteasome.
TRIM5αrh is polyubiquitylated
As protein turnover by the proteasome is often associated
with ubiquitylation (Hershko and Ciechanover, 1998), we
Fig. 2. Turnover of TRIM5α variants. (A) HeLa cells expressing TRIM5αrh, TRIM5γrh, TRIM5αhu or the indicated TRIM5αrh mutants were treated with 100 μg/ml of
cycloheximide (CHX) for a period of 12 h. At the indicated times after the beginning of the CHX treatment, cells were lysed. Cell lysates were Western blotted and
probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom panels). These experiments were repeated three times for each
individual construct, with similar results. (B) The density of each band in panel Awas measured using an Eagle Eye densitometer (Stratagene). The logarithm of the
percent initial amount of protein was plotted versus time (hours). The best curve was fit to the observed values. The half-life was determined by calculating the time
required for a level of 50% of the initial amount of protein to be achieved. These experiments were performed at least 3 times, and typical results are shown. (C) HeLa
cells expressing TRIMCyp, TRIMCypΔ93 or TRIMCypΔ130 tagged with a carboxy-terminal V5 epitope tag were treated with 100 μg/ml of cycloheximide (CHX)
for a period of 6 h. At the indicated times after the beginning of the CHX treatment, cells were lysed. Cell lysates were Western blotted and probed with antibodies
directed against either the V5 epitope tag (top panels) or β-actin (bottom panels). These experiments were performed three times for each individual construct, with
similar results.
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this purpose, HeLa cells stably expressing TRIM5αrh tagged
with a carboxy-terminal V5 epitope were transfected with a
plasmid expressing an HA-epitope-tagged ubiquitin. Forty-
eight hours later, cells were lysed and the lysates
precipitated with an anti-V5 antibody. The precipitates
were resolved on SDS-polyacrylamide gels and Western
blotted using anti-V5 and anti-HA antibodies (Fig. 4A).Polyubiquitylated forms of TRIM5αrh were observed;
furthermore, the steady-state level of TRIM5αrh and the
detectable amount of polyubiquitylated TRIM5αrh increased
after treatment with the proteasomal inhibitor MG115
(Fig. 4A).
As RING domains are often associated with E3 ubiquitin
ligase activity and the TRIM5δhu RING domain has been
implicated in self-ubiquitylation (Xu et al., 2003), we
Fig. 3. Effect of proteasomal inhibitors on TRIM5αrh and TRIM5αhu turnover. (A) HeLa cells expressing TRIM5αrh and TRIM5αhu were treated with the
DMSO solvent, 100 μg/ml cycloheximide (CHX) and/or 50 μM MG115 for a period of 6 h. Cells were harvested and lysed at the indicated times after the
initiation of treatment. Cell lysates were Western blotted and probed with antibodies directed against either the HA epitope tag (top panels) or β-actin (bottom
panels). (B) Curves describing TRIM5α levels as a function of time, based on the results in panel A, were generated as described in Fig. 2B legend. (C) HeLa
cells expressing TRIM5Cyp were treated with 25 μM MG115 for a period of 6 h. Cells were harvested and lysed at the indicated time points after the
initiation of treatment. Cell lysates were Western blotted and probed with antibodies directed against either the V5 epitope tag (top panel) or β-actin (bottom
panel). (D) HeLa cells expressing TRIM5αrh and TRIM5αhu were treated with the DMSO solvent, 100 μg/ml cycloheximide (CHX) and/or 50 mM ammonium
chloride for a period of 6 h. Cell lysates were processed as described in A and probed with antibodies directed against either the V5 epitope tag (top panels) or
β-actin (bottom panels).
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deleted RING domains. Compared with wild-type TRIM5αrh,
the TRIM5αrhΔ93 and TRIM5αrhΔ132 mutants exhibited
more low-molecular-weight forms suggestive of mono- and di-ubiquitylation, and fewer high-molecular-weight, presumably
polyubiquitylated, forms (Fig. 4B). Apparently, the RING
domain contributes either directly or indirectly to polyubiqui-
tylation of TRIM5αrh.
Fig. 4. TRIM5αrh is polyubiquitylated. (A) HeLa cells transduced with the control pLenti vector or a vector stably expressing TRIM5αrh tagged with a carboxy-terminal
V5 epitope were transiently transfected with a plasmid expressingHA-tagged ubiquitin. Forty-eight hours later, the cells were treated withMG115 or the DMSO solvent
control for 6 h. Subsequently, cells were lysed, and proteins in the cell lysates were precipitated with an anti-V5 antibody. The immunoprecipitates wereWestern blotted
and probed with an anti-V5 antibody for TRIM5αrh detection or an anti-HA antibody for ubiquitin detection. IP = immunoprecipitation; WB =Western blot. (B) 293T
cells were transiently transfected with the empty vector plasmid (pcDNA6.2) or plasmids expressing TRIM5αrh-V5, TRIM5αrhΔ93-V5 or TRIM5αrhΔ132-V5
together with a plasmid expressing ubiquitin-HA. Forty-eight hours later, cells were lysed and proteins in the cell lysates were precipitated with an anti-V5 antibody. The
precipitates were Western blotted and probed with an anti-V5 antibody for TRIM5αrh detection or an anti-HA antibody for ubiquitin detection.
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infection is not dependent upon the rapid degradation of these
molecules
Deletion of the RING domain reduces but does not
eliminate the antiretroviral activity of TRIM5αrh (Javanbakht
et al., 2005; Perez-Caballero et al., 2005). Simultaneousdeletion of the TRIM5αrh RING and B-box 2 domains
results in a protein that does not restrict retroviruses. As
shown above, the same deletions resulted in more stable
TRIM5α proteins. Because the TRIM5α protein interacts
with the viral capsid (Sebastian and Luban, 2005; Stremlau
et al., in press), it is possible that the rapid turnover of
TRIM5α affects the stability of the capsid and thus
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examined the relationship between TRIM5α turnover and
viral restriction.
TRIM5αrh and TRIMCyp mutants lacking the RING
domains are more stable than the corresponding wild-type
proteins (see above). During the course of our studies, we found
that a TRIM5αrh variant (TRIM5–21(RING)) bearing the
RING domain of human TRIM21 exhibited a much slower
rate of turnover than the wild-type TRIM5αrh protein (Fig. 5A).
Compared with half-lives of less than 60 min for the TRIM5αrh
and TRIMCyp proteins, the half-lives of the TRIM5αrhΔ93,
TRIMCypΔ93 and TRIM5–21(RING) proteins were 124, 900
and 210 min, respectively (Fig. 5B). To evaluate the con-
tribution of rapid degradation to HIV-1 restriction, we
challenged HeLa cells stably expressing the wild-type andFig. 5. Rapid TRIM5αrh degradation is not necessary for HIV-1 restriction. (A)
HeLa cells were established that express TRIM5αrh bearing the RING domain
of TRIM21 (TRIM5–21(RING)), with an HA epitope tag at the carboxyl-
terminus. The cells were treated with 100 μg/ml of cycloheximide (CHX) for a
period of 6 h. At the indicated times after the beginning of the CHX treatment,
the cells were lysed. Cell lysates were Western blotted and probed with
antibodies directed against either the HA epitope tag (top panels) or β-actin
(bottom panels). These experiments were repeated three times with similar
results. (B) The density of each band in panel A was measured using an Eagle
Eye densitometer (Stratagene). The logarithm of the percent initial amount of
protein was plotted versus time (hours). The best curve was fit to the observed
values. The half-life was determined by calculating the time required for a level
of 50% of the initial amount of protein to be achieved. These experiments were
performed at least 3 times, and typical results are shown. TRIMCyp and
TRIMCypΔ93 values were obtained from the experiment shown in Fig. 2C.
TRIM5αrh, TRIM5αrhΔ93 and actin values were obtained from the experiment
shown in Fig. 2B. (C) HeLa cells transduced with the empty LPCX vector or
vectors expressing TRIM5αrh, TRIM5αrhΔ93, TRIMCyp, TRIMCypΔ93 or
TRIM5–21(RING) were challenged with different amounts of HIV-1-GFP.
Infected, GFP-positive cells were counted by FACS. Similar results were
obtained in three independent experiments.mutant TRIM5αrh and TRIMCyp proteins with an HIV-1 vector
encoding green fluorescent protein (HIV-1-GFP) (Fig. 5C). The
RING domain-deleted versions of TRIM5αrh and TRIMCyp
retained substantial ability to inhibit HIV-1 infection, although
the observed HIV-1-restricting activities were less than those of
the respective wild-type proteins. The TRIM5–21(RING)
protein restricted HIV-1 infection with a potency comparable
to those of the wild-type TRIM5αrh and TRIMCyp proteins
(Fig. 5C). Thus, rapid turnover is not an absolute requirement
for the ability of TRIM5-related proteins to restrict HIV-1
infection.
TRIM5 colocalizes with polyubiquitylated proteins in
aggresome precursors
For proteins that are misfolded or that are otherwise prone
to self-associate, treatment of expressing cells with proteaso-
mal inhibitors has been shown to decrease protein turnover
and to cause accumulation of cytosolic aggregates (Johnston et
al., 1998). If the cytosolic unfolded protein response cannot
refold or de-aggregate these proteins, the aggregates are
transported in a microtubule-dependent manner to the
microtubule-organizing center (MTOC) (Johnston et al.,
2002; Riley et al., 2003). This process clears the aggregates
from the cytosol and concentrates them in a perinuclear
structure called the aggresome. Aggresomes are often
enveloped in vimentin cages and contain dynein, chaperones,
ubiquitylation enzymes and proteasomal components (Garcia-
Mata et al., 1999, 2002; Ito et al., 2002). As TRIM5αrh
appears to be rapidly cleared by the ubiquitin–proteasome
pathway, we tested if polyubiquitylated proteins colocalize
with TRIM5αrh. HeLa cells expressing TRIM5αrh with a
carboxy-terminal HA epitope tag were stained with an FITC-
conjugated anti-HA antibody and with the FK2 antibody,
which recognizes polyubiquitylated proteins (Fujimuro et al.,
1994). As has been previously observed (Javanbakht et al.,
2005; Song et al., 2005b), TRIM5αrh is present diffusely
throughout the cytoplasm as well as in cytoplasmic bodies.
The TRIM5αrh-containing cytoplasmic bodies are distinct
from the cytoplasmic stress granules associated with the
accumulation of untranslated mRNAs in cells subjected to
environmental stress (Anderson and Kedersha, 2002) (data not
shown). The TRIM5αrh protein in cytoplasmic bodies
colocalized with polyubiquitylated proteins (Fig. 6A). When
the cells were treated with the MG115 proteasomal inhibitor,
TRIM5αrh and polyubiquitylated proteins colocalized in a
perinuclear structure resembling an aggresome. Similar results
were obtained for TRIM5αhu (Fig. 8).
Because aggresome formation is dependent on transport
along microtubules (Johnston et al., 1998, 2002; Riley et al.,
2003), we tested if nocodazole, a drug that prevents microtubule
polymerization, would affect the formation of the perinuclear
structures formed by TRIM5αrh in the presence of proteasomal
inhibitors. Nocodazole treatment together with MG115 pre-
vented the formation of a discrete perinuclear structure
containing TRIM5αrh and polyubiquitylated proteins (Fig.
6A). Instead, larger cytoplasmic bodies were observed in the
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seen in untreated cells. These larger bodies were distributed
throughout the cytoplasm. Treatment of TRIM5α-expressing
cells with nocodazole alone resulted in an increase in thenumber of cytoplasmic bodies, which coalesced and partially
colocalized with cytoplasmic bodies containing polyubi-
quitylated proteins. The colocalization of TRIM5αrh and poly-
ubiquitylated proteins in cytoplasmic bodies and the effects
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TRIM5α-associated cytoplasmic structures may be aggresome
precursors.
To investigate further the possible link between TRIM5α
cytoplasmic bodies and aggresomes, we tested whether
TRIM5αrh colocalized with other proteins known to be
associated with microtubules or aggresomes (Garcia-Mata et
al., 1999). TRIM5αrh colocalized with dynein (Fig. 6B),
which is involved in a microtubule-directed transport of
cytosolic protein aggregates to the MTOC (Garcia-Mata et al.,
2002; Johnston et al., 1998, 2002; Rajan et al., 2001).
TRIM5αrh partially colocalized with the heat shock proteins,
Hsp70 and Hsp90, which act as chaperones and are involved
in the unfolded protein response (Fig. 6B) (Garcia-Mata et al.,
1999; Wigley et al., 1999). Moreover, γ-tubulin, an MTOC
marker, was located in the vicinity of the perinuclear
structures containing TRIM5αrh that formed in MG115-treatedcells (Fig. 6C). By contrast, the actin and microtubule
cytoskeleton did not localize with the TRIM5αrh-associated
structures formed after treatment with the proteasome inhibitor
MG115 (Fig. 6C). These results support an association
between TRIM5α and components of the unfolded protein
response.
The above results imply that TRIM5 levels in the cell are
maintained by continuous synthesis and rapid degradation and
that cytoplasmic bodies result when levels of synthesis
overwhelm the cell's ability to fold or degrade the TRIM5
protein. This predicts that decreasing TRIM5 synthesis should
result in a decrease in the number of cytoplasmic bodies in a
cell. To test this prediction, HeLa cells stably expressing
TRIM5αrh were treated with cycloheximide. At different
times, cells were stained with an anti-HA antibody to deter-
mine TRIM5αrh-HA distribution in the cell. Fig. 7 shows that,
by 2–4 h after cycloheximide treatment, the number of
Fig. 6. Proteasomal inhibitors cause relocation of TRIM5α to the aggresome. (A) HeLa cells expressing TRIM5αrh with an HA epitope tag were seeded on coverslips
and treated for 6 h with DMSO, 25 μMMG115, 1 μg/ml nocodazole (NOC) or MG115 and nocodazole. Attached cells were first stained using a mouse antibody, FK2,
directed against polyubiquitylated proteins and a secondary antibody against mouse IgG1 labeled with Cy3 (red). Subsequently, TRIM5αrh was detected by using an
anti-HA antibody conjugated to FITC (green). (B) HeLa cells expressing HA epitope-tagged TRIM5αrh were seeded on coverslips and stained with an anti-HA
antibody conjugated to FITC. Cells were also stained with anti-dynein, anti-Hsp70 and anti-Hsp90 antibodies. These proteins were detected using anti-mouse IgG1
conjugated to Alexa Fluor 568 (red) from Molecular Probes. Confocal images were taken using a 60× objective. (C) HeLa cells expressing TRIM5αrh with an HA
epitope tag were seeded on coverslips and treated with DMSO or 25 μMMG115 for a period of 6 h. Cells were stained using an anti-α-tubulin antibody (Molecular
Probes), phalloidin conjugated to Alexa Fluor 568 (red) to detect actin, or an anti-γ-tubulin antibody (Molecular Probes). To detect α- and γ-tubulin, cells were stained
with a secondary antibody against mouse IgG1 labeled with Cy3 (red). TRIM5αrh was detected as previously described (green).
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Fig. 7. TRIM5α cytoplasmic bodies are maintained by protein synthesis. HeLa
cells expressing TRIM5αrh with a carboxy-terminal HA epitope tag were seeded
on coverslips. Cells were treated with 100 μg/ml cycloheximide (CHX) for the
indicated times (hours). Cells were stained with an FITC-conjugated anti-HA
antibody. Confocal images were taken using a 60× objective. Cytoplasmic
bodies were counted in 200 randomly chosen cells at each time point. The
counts were performed in triplicate, and means and standard deviations are
reported.
310 F. Diaz-Griffero et al. / Virology 349 (2006) 300–315cytoplasmic bodies in the cells decreased dramatically, as
predicted.
Previous studies indicated that the integrity of the RING
domain of TRIM5αrh could influence the subcellular
localization of the protein (Javanbakht et al., 2005). To
examine the contribution of the RING, B-box 2 and B30.2
(SPRY) domains to association of TRIM5α with aggre-
somes, cells expressing TRIM5 variants were treated with
DMSO or MG115 and stained with an antibody against the
HA epitope at the carboxyl-terminus of the TRIM5 proteins.
In the absence of the proteasomal inhibitor, TRIM5αhu,
TRIM5αrh and TRIM5γrh exhibited diffuse cytoplasmic
staining as well as cytoplasmic body formation (Fig. 8).
MG115 treatment resulted in the localization of all three
proteins in perinuclear structures resembling aggresomes.
Deletion of the TRIM5αrh RING domain resulted in
relocalization of the TRIM5αrhΔ93 protein to nuclear
bodies, with some faint and diffuse cytoplasmic staining.
The staining pattern of the TRIM5αrhΔ93 proteins was not
significantly affected by MG115 treatment (Fig. 8). The
TRIM5αrh C15A/C18A mutant, in which alteration of the
RING domain cysteines involved in zinc binding is thought
to disrupt the folding of the domain, was located in
perinuclear bodies that became more intense upon treatment
with MG115 (Fig. 8). The TRIM5αrh C97A/H100A mutant
with a disrupted B-box 2 domain was located in the cytosol in
the absence of MG115 treatment (Fig. 8). The TRIM5αrhΔ132
mutant lacking the RING and B-box 2 domains was located
throughout the untreated cells, in both nuclear and cytoplasmiccompartments (Fig. 8). Both TRIM5αrh C97A/H100A and
Δ132 mutant proteins were found in aggresome-like structures
after treatment of the cells with MG115. It appears that the
RING, B-box 2 or B30.2(SPRY) domains are not absolutely
required for TRIM5αrh association with the aggresome.
Autophagosome inhibition does not affect restriction activity of
TRIM5α and TRIMCyp
Aggregate-prone proteins are, in some instances, dependent
upon autophagy for clearance (Mizushima et al., 2002; Reggiori
and Klionsky, 2005). Autophagy involves sequestration of a
portion of the cytosol within autophagosomes, which fuse with
lyosomes to allow degradation of their contents. Cytoplasmic
inclusion bodies associated with neurodegenerative protein
aggregates have been shown to be susceptible to autophagic
degradation (Ravikumar et al., 2002; Webb et al., 2003; Cuervo
et al., 2004; Iwata et al., 2005). To test whether autophagy is
involved in TRIM5α clearance, we monitored the steady-state
levels of TRIM5αrh in the presence of 3-methyladenine, an
inhibitor of class III phosphatidylinositol 3-kinases that has
been shown to block the formation of the autophagosome (Aki
et al., 2003; Blommaart et al., 1997; Qin et al., 2003; Ravikumar
et al., 2002). The steady-state levels of soluble TRIM5αrh
protein were not affected by 3-methyladenine treatment (Fig.
9A). However, treatment with this drug did result in an increase
in the size of the TRIM5αrh-associated cytoplasmic bodies (Fig.
9B). The ability of TRIM5αrh and TRIMCyp to restrict HIV-1
infection was not affected by 3-methyladenine treatment (Fig.
9C). Thus, autophagy may contribute to the processing of
TRIM5α cytoplasmic bodies but is not necessary for the
antiviral activity of TRIM5αrh or TRIMCyp.
Discussion
Like many cytoplasmic TRIM proteins (Reymond et al.,
2001), TRIM5α forms cytoplasmic bodies in addition to
exhibiting a more diffuse cytosolic staining pattern. The nature,
composition and function of these cytoplasmic bodies are
unknown. Our results reveal several unusual features of TRIM5
(Fig. 10). First, the TRIM5αhu, TRIM5αrh, TRIM5γrh and
TRIMCyp proteins undergo rapid turnover when expressed in
HeLa and Cf2Th cells, with half-lives of approximately 1 h. In
the vectors used to express these TRIM5 variants, the coding
sequences from the TRIM5 cDNA are under the control of a
strong constitutive promoter. The degradation rates of the
TRIM5 proteins play an important role in determining the
steady-state levels of the TRIM5 proteins in these transduced
cells. In most natural cells, TRIM5 is expressed in a constitutive
fashion (Reymond et al., 2001). It will be of interest to
investigate the mechanisms that regulate the synthesis and
turnover of TRIM5 messages and proteins in more natural
contexts. The availability of TRIM5 antibodies should assist
these studies.
Additional factors may play roles in establishing TRIM5
steady-state protein levels. For example, we have noted that
HeLa cells appear to tolerate slightly higher stable levels of
Fig. 8. The effect of proteasome inhibition on cellular location of TRIM5α variants. Control HeLa cells transduced with the LPCX vector or HeLa cells
expressing TRIM5αrh, TRIM5γrh, TRIM5αhu or the indicated TRIM5αrh mutants were seeded on coverslips. Attached cells were treated with the DMSO
control or 25 μM MG115 for a period of 6 h. Cells were stained with an FITC-conjugated anti-HA antibody. Confocal images were taken using a 60×
objective.
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2005). The basis for cellular limits on the amounts of TRIM5
protein that are stably tolerated is unknown. However, the
RBCC domains of some TRIM proteins, e.g., TRIM27 (Ret
finger protein) and HLS5, exert pro-apoptotic effects on cells
(Dho and Kwon, 2003; Lalonde et al., 2004). The expression of
aggregation-prone proteins in cells has also been suggested to
impair the general function of the ubiquitin–proteasome system
(Bennett et al., 2005), and, in light of the observed association
between TRIM5 and the aggresome, such effects may
contribute to cellular limits on levels of TRIM5 expression.
A second unusual feature of TRIM5, and TRIM proteins in
general, is the tendency to self-associate into large collections of
protein. Many TRIM proteins homo-oligomerize (Reymond et
al., 2001); moreover, these homo-oligomers can associate to
form higher-order structures that are detectable in cell lysates
and probably manifest in intact cells as cytoplasmic bodies.
Cytoplasmic bodies are sensitive to the amount of TRIM5α
protein present in the cell; the size of TRIM5α-associated
cytoplasmic bodies decreases when TRIM5α synthesis is
decreased, as upon cycloheximide treatment. Conversely, the
size and/or number of cytoplasmic bodies increase when
pathways for TRIM5α degradation are suppressed, as when
the proteasome or microtubule-dependent transport pathway isinhibited. Treatment of cells with proteasome inhibitors results
in the coalescence of TRIM5α-containing cytoplasmic bodies
into aggresomes. Most proteins do not move into aggresomes
upon inhibition of the proteasome. Mutant proteins prone to
unfolding have been shown to exhibit higher propensity to be
incorporated into aggresomes upon proteasomal inhibition
(Garcia-Mata et al., 2002; Ito et al., 2002; Johnston et al.,
1998; Wigley et al., 1999). Aggregate-prone proteins associate
with chaperones, which break up the aggregates and refold
aberrant proteins into native conformations (Garcia-Mata et
al., 2002; Johnston et al., 1998; Wigley et al., 1999). It is
likely that such processes operate on TRIM5 and other
polyubiquitylated proteins in the context of the cytoplasmic
body. Indeed, inhibition of the chaperone Hsp90 by
geldanamycin resulted in the reduction or disappearance of
TRIM5α-associated cytoplasmic bodies (Song et al., 2005b).
Proteasomal inhibition in the cells overexpressing TRIM5
apparently overwhelms the cytosolic unfolded protein re-
sponse, triggering the coalescence of the cytoplasmic bodies
into aggresomes. Thus, cytoplasmic bodies probably represent
aggresomal precursors, linked to the aggresome by microtu-
bular transport.
Our results suggest that the TRIM5αrh RING and B-box 2
domains play roles in the polyubiquitylation and turnover of the
Fig. 9. Inhibition of autophagosomes affects the size of cytoplasmic bodies but
does not disrupt retroviral restriction. (A) Cf2Th cells expressing HA-tagged
TRIM5αrh were treated with 10 mM 3-methyladenine (3-MA) (Sigma) for a
period of 18 h. At the indicated times after the beginning of the 3-MA treatment,
cells were lysed. Cell lysates were Western blotted and probed with antibodies
directed against either the HA epitope tag (top panels) or β-actin (bottom
panels). These experiments were repeated three times with similar results. (B)
Cf2Th cells expressing HA-tagged TRIM5αrh were grown on 12 mm coverslips
and treated with 10 mM 3-MA for a period of 3 and 12 h. Cells were fixed and
stained using an FITC-conjugated anti-HA antibody, as described in Materials
and methods. (C) Cf2Th cells transduced with the empty LPCX vector or
vectors expressing TRIM5αrh and TRIMCyp were challenged with different
amounts of HIV-1-GFP, in the presence or absence of 3-MA. These experiments
were repeated three times with similar results.
Fig. 10. Synthesis and turnover of TRIM5α. The diagram depicts the high rates
of synthesis and proteasomal degradation of TRIM5α. Excess free TRIM5α
may aggregate and become incorporated into cytoplasmic bodies. The
cytoplasmic bodies apparently migrate along microtubules to the perinuclear
region, where they coalesce into the aggresome at the microtubule-organizing
center. The sites of action of some of the drugs used herein and in another study
(Song et al., 2005b) to alter TRIM5α synthesis, turnover or intracellular fate are
depicted.
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domains had additive effects on the turnover rate of TRIM5αrh.
TRIM5αrh variants lacking the RING or RING/B-box 2
domains exhibited fewer polyubiquitylated forms than the
wild-type protein, even though mono- and di-ubiquitylated
forms were evident for these mutants. It is plausible that the
phenotypes of these variants with respect to polyubiquitylation
and turnover rate are related. Whether the TRIM5α RING and/
or B-box 2 domains contribute directly or indirectly to these
phenotypes requires further investigation. RING domains often
promote protein–protein interactions important for cellular
functions (Borden, 2000; Borden and Freemont, 1996; Saurin et
al., 1996). RING domains from diverse proteins, including
AO7, Praja1, Kf-1, NFX-1 and TRC8, have been demonstrated
to possess in vitro E3 ubiquitin ligase activity allowing self-
polyubiquitylation (Lorick et al., 1999). TRIM5δ has been
reported to be capable of self-ubiquitylation in vitro (Xu et al.,
2003). B-box domains have also been shown to contribute
directly or indirectly to protein–protein interactions (Cao et al.,
1997, 1998; Torok and Etkin, 2001).
Although the RING and B-box 2 domains contribute to
TRIM5αrh turnover and polyubiquitylation, they are notabsolutely required for TRIM5 localization in pre-aggresomal
structures, as the TRIM5αrhΔ132 proteins are found in
aggresomes after MG115 treatment. One caveat in interpreting
the contributions of particular domains to TRIM5 localization is
that proteins missing domains may be more prone to
aggregation due to lack of natural interdomain interactions.
Thus, even though RING, B-box and coiled-coil domains are
often treated as functionally independent entities, there is
evidence to support the notion that RBCC domains work as an
integral unit. Alterations in multiple RBCC regions of TRIM19
(PML) can result in disruption of nuclear bodies (Borden et al.,
1995, 1996). Substitution of the TRIM19 (PML) RING and B-
box domains with heterologous RING or B-box domains does
not rescue TRIM19 (PML) function (Borden, 2000). Thus,
observed associations of TRIM5 variants with cytoplasmic
bodies or aggresomes may result from disruption of the natural
context of the RBCC domains rather than the discrete
disruption of a single domain important per se for localization
in the cell.
TRIM5α is thought to interact with the incoming capsid of
the restricted virus (Sebastian and Luban, 2005; Stremlau et
al., in press). Hypothetically, the bound capsid could
passively undergo rapid turnover as a result of the association
with the unstable TRIM5α protein, contributing to the
restriction of infection. However, polyubiquitylation and/or
rapid turnover of TRIM5α appear not to be essential for
retroviral restriction. Disruption of the RING domain of
TRIM5αrh diminishes, but does not eliminate, the ability to
restrict HIV-1 infection (Fig. 5C) (Javanbakht et al., 2005;
Perez-Caballero et al., 2005). Some of this diminution in
antiviral activity is likely due to the mislocalization of the
protein in the nucleus (in the case of the TRIM5αrhΔ93
mutant) or in perinuclear structures (in the case of the
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domain is a very stable protein but still exhibits good anti-
HIV-1 activity. Likewise, a TRIM5αrh variant containing the
RING domain of TRIM21 exhibited a slower turnover
compared to wild-type TRIM5αrh. However, this chimera
restricted HIV-1 infection as potently as wild-type TRIM5αrh.
Finally, inhibition of the proteasome by clasto-lactacystin β-
lactone did not diminish the HIV-1-restricting activity of
TRIM5αrh (Stremlau et al., in press). These experiments
suggest that polyubiquitylation and/or rapid turnover is not
required for TRIM5αrh antiretroviral activity. Nonetheless, the
high rates of TRIM5α and TRIMCyp turnover create
opportunities for the rapid regulation of the levels of these
proteins in response to viral infection or other stimuli. Further
studies should shed light on these possibilities.
Materials and methods
Plasmid construction
The plasmids expressing wild-type and mutant TRIM5αrh
were constructed by polymerase chain reaction (PCR) ampli-
fication of TRIM5αrh cDNA, as previously described (Stremlau
et al., 2004). The amplified fragments were cloned into the
EcoRI and ClaI sites of pLPCX (Stratagene). The plasmids
expressing TRIM5αrh-V5 and TRIMCyp were constructed by
inserting PCR-amplified TRIM5αrh or TRIMCyp cDNA into
the Viral Power plasmid using directional TOPO® cloning
(Invitrogen). Plasmids expressing TRIM5αrh with single
amino-acid changes were created by QuikChange mutagenesis
(Stratagene). The nomenclature for these mutants is TRIM5αrh
followed by the wild-type amino acid residue in single-letter
code, amino acid position and the amino acid residue to which
the change was made.
Creation of cells stably expressing TRIM5α and TRIMCyp
variants
Retroviral vectors encoding wild-type or mutant TRIM5αrh
proteins were created using the pLPCX vector plasmid
(Stremlau et al., 2004). The pLPCX vectors contain only the
amino acid coding sequence of the TRIM5α cDNA. The
TRIM5αrh proteins encoded by the pLPCX vectors possess C-
terminal epitope tags derived from influenza hemagglutinin
(HA). Recombinant viruses were produced in 293T cells by
cotransfecting the pLPCX plasmids with the pVPack-GP and
pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-
VSV-G plasmid encodes the vesicular stomatitis virus (VSV) G
envelope glycoprotein, which allows efficient entry into a wide
range of vertebrate cells.
TRIM5αrh-V5 and TRIMCyp-V5 proteins were expressed
using the Viral Power system (Invitrogen). The TRIM5αrh-V5
and TRIMCyp-V5 proteins possess a V5 C-terminal epitope
tag. Recombinant lentiviruses were produced according to the
manufacturer's protocol (Invitrogen). The resulting virus
particles were used to transduce approximately 1 × 106 HeLa
cells in the presence of 5 μg/ml polybrene. Cells were selectedin either 1 μg/ml puromycin (Sigma) or 2 μg/ml blasticidin
(Invitrogen).
Determination of TRIM5 and TRIMCyp half-life
HeLa cells expressing the different TRIM5 variants were
seeded in 6-well plates at 40% confluency 1 day prior to the
experiment. Cells were treated with 100 μg/ml of cyclohexi-
mide (Sigma) to block protein synthesis and harvested at
different time points. Cell lysates were prepared and Western
blotted using the anti-HA antibody 3F10 (Roche). Protein band
densities were determined using Eagle Eye II (Stratagene). The
half-life of the protein was calculated by plotting the log
(percent initial amount of protein) versus time in hours.
Proteasomal inhibitors MG115 and clasto-lactacystin β-lactone
(Calbiochem) were used at 25–50 μM and 10 μM, respectively.
Ammonium chloride (Sigma) was used at 50 mM final
concentration.
Protein analysis
Cellular proteins were extracted with radioimmunoprecipi-
tation assay (RIPA) buffer (10 mM Tris, pH 7.4; 100 mM
NaCl; 1% sodium deoxycholate; 0.1% sodium dodecyl sulfate
[SDS]; 1% NP-40; 2 mg of aprotinin/ml; 2 mg of leupeptin/
ml; 1 mg of pepstatin A/ml; 100 mg of phenylmethylsulfonyl
fluoride/ml). The cell lysates were analyzed by SDS-PAGE
(10% acrylamide) followed by blotting onto nitrocellulose
membranes (Amersham Pharmacia Biotech). Detection of
protein by Western blotting utilized monoclonal antibodies
that are specifically reactive with the HA (Roche) or V5
(Invitrogen) epitope tags and monoclonal antibody against β-
actin (Sigma). Detection of proteins was performed by
enhanced chemiluminescence (NEN Life Sciences Products),
using the following secondary antibodies obtained from
Amersham Pharmacia Biotech: anti-mouse (for V5 and β-
actin) and anti-rat (for HA).
Ubiquitylation of TRIM5α
To study TRIM5α ubiquitylation, 293T cells were
transfected with plasmids encoding wild-type or mutant
TRIM5αrh together with a plasmid expressing HA-tagged
ubiquitin (kindly provided by Dr. Bettina Strack) using
Lipofectamine 2000 (Invitrogen). Forty-eight hours later, cells
were harvested and lysed in RIPA buffer. Extracts were
precipitated using a mouse anti-V5 antibody. Immunopreci-
pitated proteins were Western blotted and separately probed
with a horseradish-peroxidase (HRP)-conjugated anti-V5
antibody (Invitrogen) or an HRP-conjugated anti-HA antibody
(Roche).
Infection with viruses expressing green fluorescent protein
(GFP)
Recombinant HIV-1 expressing GFP were prepared as
described (Stremlau et al., 2004). HIV-1 viral stocks were
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infections, 3 × 104 HeLa cells seeded in 24-well plates were
incubated in the presence of virus for 24 h. Cells were washed
and returned to culture for 48 h and then subjected to FACS
analysis with a FACScan (Becton Dickinson).
Intracellular location of TRIM5 variants
Localization of TRIM5 was studied as previously de-
scribed (Diaz-Griffero et al., 2002). Briefly, cells were grown
overnight on 12-mm-diameter coverslips and fixed in 3.9%
paraformaldehyde (Sigma) in phosphate-buffered saline (PBS;
Cellgro) for 30 min. Cells were washed in PBS, incubated in
0.1 M glycine (Sigma) for 10 min, washed in PBS and
permeabilized with 0.05% saponin (Sigma) for 30 min.
Samples were blocked with 10% donkey serum (Dako,
Carpinteria, CA) for 30 min and incubated for 1 h with
antibodies. HA-tagged proteins were stained using an anti-HA
FITC-conjugated antibody, clone 3F10 (Roche). Polyubiqui-
tylated proteins were stained using a mouse monoclonal
antibody, FK2 (Affinity Research Products). Mouse mono-
clonal antibodies AC88 and C92F3A-5 against Hsp90 and
Hsp70, respectively, were obtained from Stressgen. The
mouse monoclonal antibody clone 74.1 against dynein was
obtained from Chemicon International. Monoclonal antibodies
against α- and γ-tubulin were purchased from Molecular
Probes. Actin filaments were stained using phalloidin
conjugated to Alexa 568 (Molecular Probes). Subsequently,
samples were mounted for fluorescence microscopy by using
the ProLong Antifade Kit (Molecular Probes, Eugene, OR).
Images were obtained with a BioRad Radiance 2000 laser
scanning confocal microscope with Nikon 60× N.A.1.4
optics.
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